Redeye provides a research update on Lipum following the Q4 report published by the company earlier today. Bolstered by the recent positive interim results from the ongoing phase I study with lead candidate SOL-116, Lipum announces that it is strengthening its finances through a SEK187m rights issue and is advancing the candidate into phase II trials.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/